Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1708 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-21

Study Completion Date

2025-04-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is:

To demonstrate the VRVg-2 is non-inferior to Verorab and Imovax Rabies vaccines in each age group (pediatric and adult populations) when administered as a 3-dose PrEP regimen, in terms of proportion of participants achieving a rabies virus neutralizing antibody (RVNA) titer ≥ 0.5 IU/mL at Day 42, ie. 14 days after the 3rd injection (for Primary Series Cohort 1).

The secondary objectives of this study are: First 1-5 with hypotheses testing will be evaluated sequentially - only if the previous objective is achieved, will the next objective be tested

To demonstrate that:

* the observed proportion of participants in the VRVg2(VRVg) group at D42 is at least 99% with a lower limit of the 95% confidence interval (CI) of at least 97%
* VRVg is non inferior (NI) to Verorab and Imovax Rabies vaccines (Imovax) in each age group at D28
* 2-dose VRVg at D28 is NI to 3-dose Imovax at D42 in each age group
* the observed proportion of participants in the VRVg group at D28 is at least 99% with a lower limit of the 95% CI of at least 97%
* 2-dose Imovax at D28 is NI to 3-dose Imovax at D42 in overall participants (Cohort1)

To describe:

* the immune response induced by VRVg versus Verorab and Imovax at D28 and at D42 in all age groups
* the immune response induced by VRVg at D14 after a booster dose of VRVg administered at M12 (Cohort1) and between M24 up to M36 (Cohort2)
* the persistence of immune response at M6,12,18, and pre-booster between M24 up to M36 post-primary series vaccination (Cohort2)
* safety profile of VRVg versus Verorab and Imovax in primary series and after a booster dose of VRVg

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland

NCT04478084

Rabies (Healthy Volunteers)

COMPLETED PHASE3

Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use

NCT01784874

Rabies

COMPLETED PHASE2

Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults

NCT03965962

Rabies (Healthy Volunteers)

COMPLETED PHASE3

Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy Adults

NCT00948272

Rabies

COMPLETED PHASE2

Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland

NCT04594551

Rabies (Healthy Volunteers)

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The duration of each participant's participation in the primary series Cohort 1 of the study will be approximately 7 months (28 day-vaccination period followed by 6-month safety follow-up period). For the subset of adult participants in Booster Phase Cohort 1 who received a single booster dose of VRVg-2 (1 booster dose 365 days after primary series followed by 6-month safety follow-up period), the duration will be approximately 18 months.

For Primary Series Cohort 2, the duration of each participant's participation in the study will be approximately 7 months (one week vaccination period followed by 6-month safety follow-up period).

For the subset of adult participants in Immunogenicity Persistence and Booster Phase Cohort 2 who will be followed-up for evaluation of immunogenicity persistence after primary series (including blood samples collection at M6, M12, M18, and between 24 up to 36 months) and who will receive a single booster dose of VRVg-2 (after the blood sample collection between 24 up to 36 months), the duration will be approximately 30 to 42 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rabies Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary series will be observer-blinded for both Cohort 1 (3-dose pre-exposure prophylaxis \[PrEP\] regimen) and Cohort 2 (one week 2-dose PrEP regimen).

Booster phase will be conducted in a blinded manner (vaccine received in the primary series) with an adult subset from Cohort 1 and hereafter referred as "Booster Phase Cohort 1" (with booster dose 1 year after the 1st primary series vaccine injection).

Evaluation of immunogenicity persistence after primary series and a booster phase will be conducted in an open label manner with an adult subset from Cohort 2 and hereafter referred as "Immunogenicity Persistence and Booster Phase Cohort 2" (including blood samples collection at Month 6, Month 12, Month 18, pre-booster between Month 24 up to Month 36, and post-booster between Month 24 up to Month 36+Day 14; and a booster dose between Month 24 up to Month 36).

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

For cohort 1 primary series and booster dose and cohort 2 primary series. The study is conducted in an observer-blind manner. Unblinded staff members, independent of the safety evaluation and other study evaluations, prepare and administer the vaccine. The Investigator or delegate in charge of safety assessment as well as the participants are blinded and do not know which vaccine is administered.

In addition to the participants, health care providers, data collectors, outcome assessors (eg, Investigator who assess the safety), the Sponsor personnel (eg, Clinician, Data Management, Biostatistician) will remain blinded until the first statistical analysis.

For cohort 2 immunogenicity persistence and booster phase This phase is open label, however, the laboratory analysts who will be involved in the blood sample testing will remain blinded during the whole study.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group1:VRVg2 Cohort1(C1)-1ry Series:pediatric&adult participants-Booster:102 adult participants

VRVg-2, 3 injections at Day 0, Day 7, and Day 28

Booster dose of VRVg-2 for a subset of 102 adult participants at Month 12

Group Type EXPERIMENTAL

Purified vero rabies vaccine - serum free - VRVg-2

Intervention Type BIOLOGICAL

Pharmaceutical form: Freeze-dried Route of administration: Intramuscular

Group 2:Verorab C1-1ry Series:pediatric&adult participants-Booster Phase:34 adult participants

Verorab, 3 injections at Day 0, Day 7, and Day 28

Booster dose of VRVg-2 for a subset of 34 adult participants at Month 12

Group Type ACTIVE_COMPARATOR

Purified vero rabies vaccine - serum free - VRVg-2

Intervention Type BIOLOGICAL

Pharmaceutical form: Freeze-dried Route of administration: Intramuscular

Purified inactivated rabies vaccine - Verorab®

Intervention Type BIOLOGICAL

Pharmaceutical form:Freeze-dried Route of administration: Intramuscular

Group 3:Imovax Rabies C1-1ry Series:pediatric&adult participants-Booster Phase:34 adult participants

Imovax Rabies, 3 injections at Day 0, Day 7, and Day 28

Booster dose of VRVg-2 for a subset of 34 adult participants at Month 12

Group Type ACTIVE_COMPARATOR

Purified vero rabies vaccine - serum free - VRVg-2

Intervention Type BIOLOGICAL

Pharmaceutical form: Freeze-dried Route of administration: Intramuscular

Purified inactivated rabies vaccine - Imovax® Rabies

Intervention Type BIOLOGICAL

Pharmaceutical form: Freeze-dried Route of administration: Intramuscular

Group 4:VRVg-2 Cohort 2(C2)-1ry Series:Adult participants-Booster Phase:138 adult participants

VRVg-2, 2 injections at Day 0 and Day 7

Booster dose of VRVg-2 for a subset of 138 adult participants between Month 24 up to Month 36

Group Type EXPERIMENTAL

Purified vero rabies vaccine - serum free - VRVg-2

Intervention Type BIOLOGICAL

Pharmaceutical form: Freeze-dried Route of administration: Intramuscular

Group 5:Verorab C2-1ry Series:adult participants-Booster Phase:46 adult participants

Verorab, 2 injections at Day 0 and Day 7

Booster dose of VRVg-2 for a subset of 46 adult participants between Month 24 up to Month 36

Group Type ACTIVE_COMPARATOR

Purified vero rabies vaccine - serum free - VRVg-2

Intervention Type BIOLOGICAL

Pharmaceutical form: Freeze-dried Route of administration: Intramuscular

Purified inactivated rabies vaccine - Verorab®

Intervention Type BIOLOGICAL

Pharmaceutical form:Freeze-dried Route of administration: Intramuscular

Group 6:Imovax Rabies C2-1ry Series:adult participants-Booster Phase:46 adult participants

Imovax Rabies, 2 injections at Day 0 and Day 7

Booster dose of VRVg-2 for a subset of 46 adult participants between Month 24 up to Month 36

Group Type ACTIVE_COMPARATOR

Purified vero rabies vaccine - serum free - VRVg-2

Intervention Type BIOLOGICAL

Pharmaceutical form: Freeze-dried Route of administration: Intramuscular

Purified inactivated rabies vaccine - Imovax® Rabies

Intervention Type BIOLOGICAL

Pharmaceutical form: Freeze-dried Route of administration: Intramuscular

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Purified vero rabies vaccine - serum free - VRVg-2

Pharmaceutical form: Freeze-dried Route of administration: Intramuscular

Intervention Type BIOLOGICAL

Purified inactivated rabies vaccine - Verorab®

Pharmaceutical form:Freeze-dried Route of administration: Intramuscular

Intervention Type BIOLOGICAL

Purified inactivated rabies vaccine - Imovax® Rabies

Pharmaceutical form: Freeze-dried Route of administration: Intramuscular

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged ≥1 year on the day of inclusion

* Cohort 1 - pediatrics (\>1 to 17 years old) and adult (≥18 years old)
* Cohort 2 - all adults (≥18 years old)
* Informed consent form has been signed and dated by the participant and /or and parent(s) or legally acceptable representative (LAR) and by an independent witness (if required by local regulations), as necessary; and assent form has been signed and dated by the participant, as required
* Participant (adult ≥18 years) or participant and parent/LAR (1 year to \<18 years) are able to attend all scheduled visits and to comply with all study procedures.

Exclusion Criteria

* Participant is pregnant, or lactating, or of childbearing potential and not using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination until 1 month after each vaccination. To be considered of non-childbearing potential, a female must be pre-menarche or post-menopausal for at least 1 year, or surgically sterile.
* Participation at the time of study enrollment or, planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure.
* Receipt of any vaccine in the 4 weeks (28 days) preceding the first study vaccination or planned receipt of any vaccine prior to Visit 5 for pediatric participants and adult participants in Cohort 1, and prior to Visit 4 for adult participants in Cohort 2.
* Previous vaccination against rabies (in pre- or post-exposure regimen) with either the study vaccines or another vaccine.
* Bite by, or exposure to a potentially rabid animal in the previous 6 months with or without post-exposure prophylaxis.
* Receipt of immune globulins, blood or blood-derived products in the past 3 months.
* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
* At high risk for rabies exposure during the study.
* Known systemic hypersensitivity to any of the study/control vaccine components, or history of a life-threatening reaction to the vaccines used in the study or to a vaccine containing any of the same substances.
* Self-reported thrombocytopenia, contraindicating intramuscular vaccination.
* Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination.
* Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
* Current alcohol or substance abuse that, in the opinion of the investigator, might interfere with the study conduct or completion.
* Chronic illness(1) that, in the opinion of the Investigator, is at a stage where it might interfere with study conduct or completion.
* Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38.0°C). A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
* Personal history of Guillain-Barré syndrome.
* Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.

1. Chronic illness may include, but is not limited to, neurological, cardiopulmonary, gastrointestinal, renal, genitourinary, metabolic, hematologic, auto-immune, or psychiatric disorders or infection

Minimum Eligible Age

1 Year

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes